TB-500

One important mechanism of full-length thymosin β4 is its interaction with G-actin, a protein involved in the structure and movement of the cellular cytoskeleton. This interaction can influence how cells migrate into damaged tissue during repair. Studies of thymosin β4 have reported migration of fibroblasts, keratinocytes, endothelial cells and several progenitor-cell types. The molecule has also been associated with angiogenesis, the formation of new blood vessels needed to deliver oxygen and nutrients to recovering tissue.

A large share of research concerns wound healing. Preclinical models have reported faster wound closure, improved collagen remodelling and increased formation of new capillaries after exposure to thymosin β4. In an early widely cited study, very low concentrations increased keratinocyte migration two- to three-fold, while treated wounds showed earlier epithelialisation and improved tissue structure. Later animal experiments reported similar findings, making thymosin β4 a prominent subject in regenerative research.

Anti-inflammatory activity is another area of interest. Inflammation is necessary during tissue repair, but an excessive or prolonged response can interfere with regeneration. Experimental studies suggest that thymosin β4 may reduce overproduction of inflammatory cytokines, limit secondary tissue injury and preserve immune activity required for healing. Reduced programmed cell death has also been reported in some models, potentially allowing more viable cells to remain at the injury site.

Researchers have also examined connective-tissue repair. Animal studies suggest that thymosin β4 may influence healing of tendons and ligaments, collagen-fibre organisation and the mechanical strength of recovering tissue. This is relevant because connective tissue generally heals more slowly than muscle. Most of these findings remain preclinical, and clinical effectiveness in humans has not been established.

Thymosin β4 is also studied in relation to scar formation and fibrosis. Experimental work suggests that it may affect myofibroblast activity and excessive fibrotic-tissue formation while allowing normal collagen remodelling. Research therefore extends beyond skin to models involving fibrosis of the heart, lungs, liver and kidneys.

Other experimental areas include cardiac injury, corneal healing, nervous-system damage and ischaemic tissue. Some studies after myocardial infarction reported less scar formation and improved cardiac recovery, while ocular models described enhanced corneal epithelial healing and reduced inflammation. These results are preclinical or early-stage, and many proposed indications lack large randomised clinical trials.

It is essential to distinguish natural full-length thymosin β4 from TB-500. Most publications on wound healing, angiogenesis and regeneration investigate the complete 43-amino-acid thymosin β4 molecule. TB-500 is described as a synthetic compound associated with an active sequence, but its composition and biological equivalence should not be assumed to match the full-length protein. Findings from thymosin β4 therefore cannot automatically be assigned to TB-500, and direct human clinical evidence for TB-500 is extremely limited.